Immunwork
CompanyTaiwan
Immunwork develops one asset, in phase 2 (TE-8105 in overweight and obesity). Mostly peptide acting on lipid and ceramide metabolism; based in Taiwan.
- 1
- Asset
- Furthest
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Investigational therapy for overweight or obesity
Phase 2, Peptide, Lipid and ceramide metabolism, overweight and obesity
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6
Updated 7 Oct 2026 · 2 sources